Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/48342Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | HELLINGS, Niels | - |
| dc.date.accessioned | 2026-02-02T10:05:09Z | - |
| dc.date.available | 2026-02-02T10:05:09Z | - |
| dc.date.issued | 2026 | - |
| dc.date.submitted | 2026-01-23T11:43:13Z | - |
| dc.identifier.citation | Multiple Sclerosis Journal, | - |
| dc.identifier.uri | http://hdl.handle.net/1942/48342 | - |
| dc.description.sponsorship | Funding The author received no financial support for the research, authorship, and/or publication of this article. | - |
| dc.language.iso | en | - |
| dc.publisher | SAGE PUBLICATIONS LTD | - |
| dc.rights | The Author(s), 2026. Article reuse guidelines: sagepub.com/journalspermissions | - |
| dc.title | Targeting EBV is a viable therapeutic strategy in MS: No | - |
| dc.type | Journal Contribution | - |
| local.format.pages | 3 | - |
| local.bibliographicCitation.jcat | A2 | - |
| dc.description.notes | Hellings, N (corresponding author), Hasselt Univ, Biomed Res Inst, Dept Immunol & Infect, Neuroimmune Connect & Repair NIC&R Lab, Martelarenlaan 42, B-3500 Hasselt, Belgium. | - |
| dc.description.notes | niels.hellings@uhasselt.be | - |
| local.publisher.place | 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND | - |
| local.type.refereed | Refereed | - |
| local.type.specified | Editorial Material | - |
| local.bibliographicCitation.status | Early view | - |
| local.class | dsPublValOverrule/author_version_not_expected | - |
| dc.identifier.doi | 10.1177/13524585251409970 | - |
| dc.identifier.isi | 001662884400001 | - |
| local.provider.type | wosris | - |
| local.description.affiliation | [Hellings, Niels] Hasselt Univ, Biomed Res Inst, Dept Immunol & Infect, Neuroimmune Connect & Repair NIC&R Lab, Diepenbeek, Belgium. | - |
| local.description.affiliation | [Hellings, Niels] Univ MS Ctr UMSC, Diepenbeek Pelt, Belgium. | - |
| local.uhasselt.international | no | - |
| item.fulltext | With Fulltext | - |
| item.contributor | HELLINGS, Niels | - |
| item.fullcitation | HELLINGS, Niels (2026) Targeting EBV is a viable therapeutic strategy in MS: No. In: Multiple Sclerosis Journal,. | - |
| item.accessRights | Restricted Access | - |
| crisitem.journal.issn | 1352-4585 | - |
| crisitem.journal.eissn | 1477-0970 | - |
| Appears in Collections: | Research publications | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 13524585251409970.pdf Restricted Access | Early view | 115.06 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.